DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Tofogliflozin
Tofogliflozin
View a Copy of This Licence, Visit Tivecommons.Org/Licenses/By/4.0
Supplementary Material
Glucose Cotransporter 2 Inhibitor, Attenuates Body Weight Gain and Fat Accumulation in Diabetic and Obese Animal Models
Comparison of Tofogliflozin 20 Mg and Ipragliflozin 50 Mg Used Together
Populationsweite Utilisationsuntersuchung in Den Chronischen Krankheitsbildern Hypertonie, Hyperlipid¨Amieund Typ 2 Diabetes Mellitus –
Clinical Comparison of Tofogliflozin and Empagliflozin Based on An
Effect of Tofogliflozin on Arterial Stiffness in Patients with Type 2
Identification of SGLT2 Inhibitor Ertugliflozin As a Treatment
Pharmacokinetic and Pharmacodynamic Profile
Dapagliflozin- Induced Severe Ketoacidosis Requiring Hemodialysis Ossama Maadarani*, Zouheir Bitar and Rashed Alhamdan
Effect of Tofogliflozin on Systolic and Diastolic Cardiac Function in Type 2 Diabetic Patients
Comparison of the Efficacy and Safety of 10-Mg Empagliflozin Every Day Versus Every Other Day in Japanese Patients with Type 2 Diabetes Mellitus : a Pilot Trial
Efficacy and Safety of Dapagliflozin in the Elderly
Type 2 Diabetes Screening and Treatment Guideline | Kaiser
Multi-Country Non-Interventional Study on the Effectiveness and Safety of Empagliflozin in Adult Patients with Type 2 Diabetes in Europe and Asia
Oral Anti-Diabetic Agents-Review and Updates
Stembook 2018.Pdf
(Type 2 Diabetes) - Forecast and Market Analysis to 2022
Top View
Sotagliflozin As a Potential Treatment for Type 2 Diabetes Mellitus
The Effects of SGLT2 Inhibitors on Lipid Metabolism
Comparative Effectiveness of Sodium- Glucose Co-Transporter 2 Inhibitors
Adverse Effects and Safety of SGLT2 Inhibitor Use Among Patients with Type 2 Diabetes: Findings from RCT Evidence
2020 Diabetes Guideline Data Supplement
Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes Mellitus
Sodium-Dependent Glucose Cotransporters
A SELECTIVE SGLT2 Inhibitor) in Patients with Type 2 Diabetes Mellitus
Impact of the 8-Week Administration of Tofogliflozin for Glycemic Control and Body Composition in Japanese Patients with Type 2 Diabetes Mellitus
DIABETOLOGY SGLT2 Inhibitors: a Novel Therapy for Type 2 Diabetes Mellitus
Downloaded From
Clinical Therapeutics/New Technology— Glucose Monitoring and Sensing 2348‑Pub
Protocol for Non-Interventional Studies Based on Existing Data TITLE PAGE Document Number: C26457869-01
Tofogliflozin: a Highly Selective Sglt2 Inhibitor for the Treatment of Type 2 Diabetes
Type 2 Diabetes Mellitus That Is Hitting Back With
Empagliflozin Reverses Obesity and Insulin Resistance Through Fat Browning and Alternative Macrophage Activation in Mice Fed a High-Fat Diet
Emerging Roles of SGLT2 Inhibitors in Obesity and Insulin Resistance: Focus on Fat Browning and Macrophage Polarization
Risks Vs Benefits for SGLT2 Inhibitor Medications
Australasian Anaesthesia 2019
3/23/2015 1 Medications Update – New and Emerging Therapies
Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes
Discovery Awaits You at the 81ST Scientific Sessions
RFP) Significant Renal Protection Was Observed of Sglt2i Over Placebo2
Association Between Dipeptidyl Peptidase-4 Inhibitors and Autoimmune Disorders: Data Mining of the Spontaneous Reporting System in Japan
Role of Selective Sodium-Glucose Co-Transporter- 2 Inhibitors in Managing Cardio-Renal Complications in Type 2 Diabetes Mellitus
International Journal of Geriatrics and Gerontology Higashikawa T, Et Al
“Sodium-Glucose Transporter 2 Inhibitors” [Mesh Terms] OR SGLT2 Inhibitors
A Significance of Sodium-Glucose Cotransporter 1 (SGLT1) Inhibition
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Association Between Use of Sodium-Glucose Cotransporter 2
Choosing the Best Oral Diabetic Agents in T2 Diabetes Mellitus
Case Report Combination Therapy with Empagliflozin and Insulin
12-Cem-Diabetes-Hand
Central Administration of Sodium-Glucose Cotransporter-2
Identification and Characterization of Antidiabetic And
Sodium–Glucose Transporter-2 Inhibitors for Prevention And
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents